Detalles de la búsqueda
1.
Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma.
JTO Clin Res Rep;
5(1): 100613, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38229769
2.
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).
Cancer Sci;
115(4): 1273-1282, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38287788
3.
Successful application of lorlatinib in a 23-year-old patient with anaplastic lymphoma kinase (ALK)-positive lung cancer and multiple brain metastases.
Cancer Rep (Hoboken);
7(2): e1981, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38212894
4.
Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report.
J Thorac Oncol;
19(2): 337-343, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37943237
5.
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.
JAMA Oncol;
10(1): 43-51, 2024 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37991747
6.
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study.
JTO Clin Res Rep;
4(12): 100593, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38046378
7.
Efficacy of paclitaxel-carboplatin with bevacizumab as a late-line therapy for patients with advanced nonsquamous non-small cell lung cancer: A platinum rechallenge.
Thorac Cancer;
14(31): 3140-3146, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37699787
8.
Phase II trial of daily S-1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101.
Thorac Cancer;
14(27): 2804-2810, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37589158
9.
A retrospective study of the efficacy of combined EGFRTKI plus VEGF inhibitor/cytotoxic therapy vs. EGFRTKI monotherapy for PDL1positive EGFRmutant nonsmall cell lung cancer: North Japan Lung Cancer Study Group 2202.
Oncol Lett;
26(2): 334, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37427337
10.
Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02).
Cancer Chemother Pharmacol;
92(1): 29-37, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37243795
11.
Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003).
Thorac Cancer;
14(1): 105-107, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36380738
12.
Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01).
Thorac Cancer;
14(2): 168-176, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36408699
13.
A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630.
Clin Cancer Res;
28(20): 4402-4409, 2022 10 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35980349
14.
Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).
Thorac Cancer;
13(10): 1471-1478, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35415873
15.
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.
Lancet Respir Med;
10(1): 72-82, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34454653
16.
Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers.
PLoS One;
16(11): e0260500, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34843570
17.
Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.
Cancer Med;
10(14): 4796-4804, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34121358
18.
Development and evaluation of a novel quenching probe PCR (GENECUBE) assay for rapidly detecting and distinguishing between Chlamydia pneumoniae and Chlamydia psittaci.
J Microbiol Methods;
184: 106212, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33781806
19.
Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302.
Int J Clin Oncol;
26(3): 515-522, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33184754
20.
Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab.
JMA J;
3(1): 58-66, 2020 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33324776